Conversely, administering an AhR antagonist to mice worsens TNBS-induced colitis (Benson and Shepherd, 2011), suggesting that AhR activation can mitigate intestinal inflammation, thus proposing AhR as a ‘new target’ for IBD treatment. Here, AHR is linked to colitis.